Spero Therapeutics Appoints William Ho, M.D., Ph.D., to its Board of Directors
Key Highlights
- ➤Spero Therapeutics appoints William Ho, M.D., Ph.D., to its Board and Development Committee
- ➤Patrick Vink steps down after an eleven-year Board tenure
- ➤GSK’s $2.2 billion acquisition of RAPT Therapeutics finalized in March 2026
- ➤SP001 advances first in IgG4-related disease, with potential additional indications
Expert Statements
Frank Thomas, Chairman of the Board of Spero Therapeutics
“We are pleased to welcome Bill to Spero’s Board of Directors as Spero executes on its immunology-focused strategy, including advancing SP001 and evaluating opportunities to expand its pipeline”
Frank Thomas, Chairman of the Board of Spero Therapeutics
“We believe that Bill’s strong background in immunology and extensive experience with translational and clinical development, including the development of an immunology asset originating from China while at RAPT Therapeutics, will bring valuable and relevant perspective to the Board as we advance our strategy and work to create long-term value for patients and shareholders.”
Frank Thomas, Chairman of the Board of Spero Therapeutics
“We are deeply grateful to Patrick for his invaluable contributions to the Company and the Board of Directors during his eleven-year tenure”
Frank Thomas, Chairman of the Board of Spero Therapeutics
“His leadership has been instrumental in advancing Spero through its IPO to an established public company with an approved drug that is now strategically positioned for its next phase of growth. We wish him the very best in his future endeavors.”
William Ho, Director of Spero Therapeutics
“I am excited to join Spero’s Board at this important stage in the Company’s evolution”
William Ho, Director of Spero Therapeutics
“Spero has an exciting opportunity with SP001 and its broader focus on developing therapies for patients with serious immune-mediated diseases.”
CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines for patients with serious immune-mediated diseases, today announced the appointment of William Ho, M.D., Ph.D., to its Board of Directors, and its Development Committee, effective as of November 10, 2026. Concurrently, the Company announced that Dr. Patrick Vink will step down from the Board of Directors, with Dr. Ho filling the vacancy created by Dr. Vink’s departure.
“We are pleased to welcome Bill to Spero’s Board of Directors as Spero executes on its immunology-focused strategy, including advancing SP001 and evaluating opportunities to expand its pipeline,” said Frank Thomas, Chairman of the Board of Spero Therapeutics. “We believe that Bill’s strong background in immunology and extensive experience with translational and clinical development, including the development of an immunology asset originating from China while at RAPT Therapeutics, will bring valuable and relevant perspective to the Board as we advance our strategy and work to create long-term value for patients and shareholders.”
Get started
Create a free account to read the full story.